TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: ERIS · data 2026-11-02
Eris Lifesciences Ltd
In plain words
Price: 31.9% below its 52-week high of ₹1,740.
Delivery: 45.0% of traded shares were kept for delivery over the last 10 sessions, against 54.8% over the last 60.
Latest results: a net profit of ₹184 cr for the quarter ended Sept 2026 (+52.9% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹3,330 cr |
| Net profit (last 12 months) | ₹708 cr |
| Sales growth, 3 years (yearly) | 22.9% |
| Profit growth, 3 years (yearly) | 17.5% |
At a glance
Promoters 54.7% (-0.1 pts in a year), pledged 21.3%, institutions 25.9%.
P/E 23.1, P/B 4.0, dividend yield 0.6%. Price relative to earnings and book value (low is cheaper, not better).
ROE 18.3%, ROCE 15.6%, operating margin 26.3%: how much profit it earns on the money it uses.
Debt/equity 0.60, Profit growth 17.5% and sales growth 22.9% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (18.3%).
- Healthy operating margin (26.3%).
- Profit grew 17.5% a year over 3 years.
- Promoters have pledged 21.3% of their shares.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
ERIS Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹892.37 crore, up 12.6% YoY and up 2.2% QoQ.
Net profit was ₹183.82 crore, up 52.9% YoY and up 29% QoQ.
Operating margin was 34.7% (36.4% a year ago).
EPS was ₹13.26, up 50.3% YoY and up 29% QoQ.
ERIS के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹892.37 करोड़; पिछले साल की तुलना में 12.6% की बढ़त, पिछली तिमाही की तुलना में 2.2% की बढ़त।
शुद्ध मुनाफ़ा: ₹183.82 करोड़; पिछले साल की तुलना में 52.9% की बढ़त, पिछली तिमाही की तुलना में 29% की बढ़त।
ऑपरेटिंग मार्जिन: 34.7% (एक साल पहले 36.4%)।
EPS: ₹13.26; पिछले साल की तुलना में 50.3% की बढ़त, पिछली तिमाही की तुलना में 29% की बढ़त।
ERISના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹892.37 કરોડ; ગયા વર્ષની સરખામણીએ 12.6% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 2.2% વધારો.
ચોખ્ખો નફો: ₹183.82 કરોડ; ગયા વર્ષની સરખામણીએ 52.9% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 29% વધારો.
ઓપરેટિંગ માર્જિન: 34.7% (એક વર્ષ પહેલાં 36.4%).
EPS: ₹13.26; ગયા વર્ષની સરખામણીએ 50.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 29% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
21/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 47.6% over the last 20 sessions vs 60.5% in the 40 before (0.79x); shares delivered per day 1.26x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 5/15: 2 schemes hold it, about ₹129 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 1/15: Verdict "None", sustained score 36/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 26 Oct 26Results Q2 FY27 results: profit +52.9% YoY +9.4% next session
- 29 Jul 26Results Q1 FY27 results: profit +20.7% YoY -1.1% next session
- 29 May 26Dividend Dividend ₹7.21 (ex-date) +2.0% next session
- 20 May 26Results Q4 FY26 results: profit +200.1% YoY +3.7% next session
- 13 Feb 26Results Q3 FY26 results: profit +19.2% YoY -9.7% next session
- 12 Nov 25Results Q2 FY26 results: profit +31.2% YoY -4.9% next session
- 5 Aug 25Results Q1 FY26 results: profit +41.8% YoY -4.3% next session
- 19 May 25Results Q4 FY25 results: profit +32.2% YoY +0.4% next session
- 13 Feb 25Dividend Dividend ₹7.35 (ex-date) -4.1% next session
- 5 Feb 25Results Q3 FY25 results: profit −18.6% YoY +18.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹892 cr | ₹184 cr | +52.9% | 34.7% | 13.26 |
| Jun 2026 | ₹873 cr | ₹142 cr | +20.7% | 33.9% | 10.28 |
| Mar 2026 | ₹757 cr | ₹282 cr | +200.1% | 36.2% | 20.6 |
| Dec 2025 | ₹807 cr | ₹100 cr | +19.2% | 34.9% | 7.32 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 54.74% | 54.14% | 53.92% | 54.85% |
| Foreign institutions (FII) | 5.74% | 5.75% | 6.39% | 6.85% |
| Domestic institutions (DII) | 20.20% | 20.72% | 20.35% | 20.32% |
| Mutual funds | 17.98% | 18.88% | 18.22% | 18.26% |
| Retail investors | 2.50% | 2.65% | 2.61% | 2.62% |
| Number of shareholders | 49,034 | 50,798 | 51,656 | 54,713 |
Common questions
What was Eris Lifesciences Ltd's latest quarterly profit?
Eris Lifesciences Ltd reported a net profit of ₹184 cr for the quarter ended Sept 2026 (+52.9% on the same quarter a year earlier), on revenue of ₹892 cr.
How much do promoters hold in Eris Lifesciences Ltd?
Promoters held 54.74% of Eris Lifesciences Ltd at the end of Sept 2026, with 21.25% of promoter shares pledged.
Is Eris Lifesciences Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.6.
What is Eris Lifesciences Ltd's P/E ratio?
About 23.1, based on the last 12 months' earnings and a price of ₹1,184.4 (data 2026-11-02).
What is the 52-week high and low of Eris Lifesciences Ltd?
The 52-week high is ₹1,740 and the 52-week low is ₹1,069.
Mutual funds holding Eris Lifesciences Ltd
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 2 schemes holding about ₹129 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 2.39% | ₹84 cr |
| ADITYA BIRLA SUN LIFE AGGRESSIVE HYBRID FUND | Aditya Birla Sun Life Mutual Fund | 0.66% | ₹45 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Eris Lifesciences Ltd | ₹1,184.4 | ₹16,088 cr | 23.1 | 4 | 18.3% | 15.6% | 0.6 | -27.2% |
| Cohance Lifesciences Ltd | ₹445.7 | ₹17,005 cr | 161.5 | 4.4 | 6.4% | 4.6% | 0.1 | -42.8% |
| PFIZER LIMITED | ₹3,630.6 | ₹16,867 cr | 22.6 | — | 17.2% | 20% | 0.02 | -31.8% |
| AstraZeneca Pharma India Limited | ₹6,439 | ₹15,918 cr | 94.9 | — | 23.9% | 25.5% | 0.13 | -32.0% |
| Alembic Pharmaceuticals Limited | ₹804.6 | ₹15,682 cr | 22.8 | — | 12.3% | 11.8% | 0.25 | -10.6% |
| NATCO Pharma Limited | ₹784.7 | ₹15,350 cr | 12.4 | — | 16.9% | 15.6% | 0.08 | -5.1% |
Compare ERIS with COHANCE in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ERIS in TickerKhoj →